Tradestie Institutional Equity Comparison Engine
BCAX vs RAPP โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
RAPP Overall Edge
RAPP Captures Institutional Edge (1โ1 Pillars ยท 4โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Rapport Therapeutics, Inc. Common Stock (RAPP) driven by superior Momentum & Technical while BCAX counters with relative strength in Growth & Margin. Fundamentally, BCAX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus RAPP at N/M Forward P/E and -838.1% operating margin (+0.0% YoY). In options structure, BCAX sits in BREAKDOWN (23rd %ile IV; Dealer Gamma Walls on Pro) against RAPP sits in BREAKDOWN (6th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
BCAX N/M vs RAPP N/M Fwd P/E
Growth & Margin Winner
BCAX
Op Margin 0.0% vs -838.1% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner
RAPP
1Y -31.6% vs +0.6% ยท 52W Pos 8% vs 9%
Options & Structure Winner
Tie
BREAKDOWN (23rd %ile IV) vs BREAKDOWN (6th %ile IV)
BCAX
NASDAQ
Bicara Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$9.75
-2.69% 1D
Market Cap
$665.2M
1M Return
-41.9%
1Y Return
-31.63%
Forward P/E
N/M
Unified AI Score
52.1 / 100
HOLD
Tech 58.0
Fund 66.0
Flow 68.0
Mom 64.0
RAPP
NASDAQ
Rapport Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$24.82
-5.09% 1D
Market Cap
$1.6B
1M Return
-9.97%
1Y Return
+0.61%
Forward P/E
N/M
Unified AI Score
51.4 / 100
HOLD
Tech 62.0
Fund 63.0
Flow 68.0
Mom 58.9
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
BCAX -31.63%
RAPP +0.61%
Spread: +32.24 pp (RAPP Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
BCAX TTM Op. Margin: 0.0%
RAPP TTM Op. Margin: -838.1%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BCAX vs RAPP. Trailing 12-month operating profitability (BCAX 0.0% vs RAPP -838.1%) and valuation multiples (BCAX N/M vs RAPP N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | BCAX | RAPP | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $665.2M | $1.6B | Larger Scale | RAPP |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +0.0% | Higher Growth | Tie |
| Operating Margin (TTM) Profitability | 0.0% | -838.1% | Higher Margin | BCAX |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -54.2% | -33.3% | Higher ROE | RAPP |
| 52-Week Range Position Momentum | 8% ($8โ$31) | 9% ($22โ$53) | Stronger Trend | RAPP |
| Beta / 30D Volatility Risk Regime | 1.42ฮฒ ยท 184% Vol | 1.31ฮฒ ยท 108% Vol | Lower Realized Risk | RAPP |
| Unified Institutional Score Composite Signal | 52.1 / 100 (HOLD) | 51.4 / 100 (HOLD) | Higher Composite | BCAX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full BCAX vs RAPP Buy Guide
BCAX
BREAKDOWN
93d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
23rd %ile
IV Regime
Compressed (<25th %ile)
RAPP
BREAKDOWN
133d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
6th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither BCAX nor RAPP registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.